All this bashing about Insmed not pursuing CF in the US, how TIP has the CF Pa market and Arikace/Arikayce doesn't stand a chance is mindless misdirection. They want to create a message that CF is the game.
The NTM market is bigger than CF. The NTM market has no competitors, unlike CF. The non-US NTM market is larger than the US. Global market barriers to NTM are non-existent. This is why Insmed will be discussing with the EMA the possibility of a joint filing. Don't be mislead by the CF misdirect.